HS-10506 / Jiangsu Hansoh Pharma - LARVOL DELTA

Study on the Pharmacokinetic Effect of Omeprazole Magnesium Enteric-coated Tablets on HS-10506 Tablets (ChiCTR) - P1 | N=18 | Completed | Sponsor: The Third Xiangya Hospital Central South University; The Third Xiangya Hospital Central South University

New P1 trial • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

A randomised, double-blinded, placebo-controlled, single ascending dose study of HS-10506 in healthy subjects (ECNP 2024) - "Overall, HS-10506 was safe and well-tolerated ranging from dose 2.5 mg to 60 mg. PK profile, particularly the relatively short Tmax and half-life, and dose-related somnolence indicate the therapeutic potential of HS-10506 for insomnia."

Clinical • CNS Disorders • Insomnia • Sleep Disorder

Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder (clinicaltrials.gov) - P1/2 | N=312 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1/2 trial • CNS Disorders • Insomnia • Sleep Disorder

Phase 1a Study in Healthy Participants (clinicaltrials.gov) - P1a | N=52 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial